A COMPARATIVE-STUDY OF THE ACTIONS OF TAMOXIFEN, ESTROGEN AND PROGESTERONE IN THE OVARIECTOMIZED RAT

被引:84
作者
KALU, DN
SALERNO, E
LIU, CC
ECHON, R
RAY, M
GARZAZAPTA, M
HOLLIS, BW
机构
[1] UNIV TEXAS,HLTH SCI CTR,DEPT OBSTET & GYNECOL,SAN ANTONIO,TX 78284
[2] AMER LAKE VET ADM MED CTR,TACOMA,WA
[3] UNIV WASHINGTON HOSP,DEPT MED,SEATTLE,WA 98195
[4] MED UNIV S CAROLINA,CHARLESTON,SC 29425
来源
BONE AND MINERAL | 1991年 / 15卷 / 02期
关键词
OVARIECTOMY; ESTROGEN; TAMOXIFEN; BONE LOSS;
D O I
10.1016/0169-6009(91)90002-H
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study was undertaken to examine the separate and combined effects of tamoxifen (T), estrogen (E2) and progesterone (P) treatment on ovariectomized (Ooph) rats. The animals were treated for 40 days. Ovariectomy reduced cancellous bone volume at the proximal tibia by 50%. Estradiol treatment completely prevented the bone loss and further increased bone volume 77% over the level for the control group. Tamoxifen also prevented the ovariectomy induced bone loss, but significantly reduced the increase in cancellous bone induced by estradiol. In the ovariectomized rats, cancellous bone apposition rate increased 23%. This increase was suppressed 63% by estradiol, and only 18% by tamoxifen. Tamoxifen significantly suppressed the inhibitory effect of estradiol on cancellous bone apposition rate. In contrast, the effect of progesterone treatment was only marginal. Our findings indicate that the action of tamoxifen on bone is influenced by the ambient level of circulating estradiol, such that in estrogen deficiency, tamoxifen has a weak estrogen agonist action on bone, and in the presence of estrogen it has anti-estrogen actions, with the dose level and mode of administration employed. These conclusions have implications for the use of tamoxifen in the treatment of pre- and postmenopausal women.
引用
收藏
页码:109 / 123
页数:15
相关论文
共 43 条
[11]   ANTIESTROGEN AND ANTIANDROGEN ADMINISTRATION REDUCE BONE MASS IN THE RAT [J].
FELDMANN, S ;
MINNE, HW ;
PARVIZI, S ;
PFEIFER, M ;
LEMPERT, UG ;
BAUSS, F ;
ZIEGLER, R .
BONE AND MINERAL, 1989, 7 (03) :245-254
[12]   TREATMENT OF PRIMARY BREAST-CANCER WITH CHEMOTHERAPY AND TAMOXIFEN [J].
FISHER, B ;
REDMOND, C ;
BROWN, A ;
WOLMARK, N ;
WITTLIFF, J ;
FISHER, ER ;
PLOTKIN, D ;
BOWMAN, D ;
SACHS, S ;
WOLTER, J ;
FRELICK, R ;
DESSER, R ;
LICALZI, N ;
GEGGIE, P ;
CAMPBELL, T ;
ELIAS, EG ;
PRAGER, D ;
KOONTZ, P ;
VOLK, H ;
DIMITROV, N ;
GARDNER, B ;
LERNER, H ;
SHIBATA, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1981, 305 (01) :1-6
[13]   ESTROGENS AND PROGESTOGENS CONSERVE BONE IN RATS DEFICIENT IN CALCITONIN AND PARATHYROID-HORMONE [J].
GOULDING, A ;
GOLD, E .
AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 257 (06) :E903-E908
[14]   ESTRADIOL STIMULATES INVITRO THE SECRETION OF INSULIN-LIKE GROWTH-FACTORS BY THE CLONAL OSTEOBLASTIC CELL-LINE, UMR106 [J].
GRAY, TK ;
MOHAN, S ;
LINKHART, TA ;
BAYLINK, DJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 158 (02) :407-412
[15]   INTERACTIONS BETWEEN THE GONADAL-STEROIDS AND THE IMMUNE SYSTEM [J].
GROSSMAN, CJ .
SCIENCE, 1985, 227 (4684) :257-261
[16]  
HOLLIS BW, 1985, CLIN CHEM, V31, P1815
[17]  
HOLLIS BW, 1986, CLIN CHEM, V32, P2060
[18]   EFFECTS OF ANTIESTROGENS ON BONE IN CASTRATED AND INTACT FEMALE RATS [J].
JORDAN, VC ;
PHELPS, E ;
LINDGREN, JU .
BREAST CANCER RESEARCH AND TREATMENT, 1987, 10 (01) :31-35
[19]  
JORDAN VC, 1984, PHARMACOL REV, V36, P245
[20]   NON-STEROIDAL ANTI-ESTROGENS - THEIR BIOLOGICAL EFFECTS AND POTENTIAL MECHANISMS OF ACTION [J].
JORDAN, VC ;
DIX, CJ ;
NAYLOR, KE ;
PRESTWICH, G ;
ROWSBY, L .
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH, 1978, 4 (2-3) :363-390